GenePlus Launches Affordable, Customized MRD Testing for Early-Stage Cancer Patients Ahead of Hong Kong IPO

MRD, i.e.Molecular Residual Disease. The so-called molecular residual disease refers to tumor-derived DNA molecules (ctDNA) that persist in the patient's blood after treatment, even when imaging studies show no evidence of disease.It can lurk throughout the body, serving as the seed for tumor metastasis and recurrence.

Studies have shown that imaging examinations have certain limitations in assessing whether residual lesions remain after treatment. Detecting MRD through ctDNA testing can serve as an effective complement to imaging examinations, thereby assisting physicians in making clinical judgments. In recent years, the value of MRD detection has been widely applied in clinical practice. It can predict patient prognosis andAssessing Treatment Efficacy; provided to cancer patientsMore Rational Treatment Regimensand in cancer patientsFollow-up Monitoringvalue is gradually being discovered and recognized.

However, as an emerging technology, MRD testing remains relatively expensive. More importantly, most MRD testing products currently available in the Chinese market are offered as fixed-frequency packages, lacking the flexibility for personalized customization based on individual patient needs. Patients typically need to make a one-time payment of tens of thousands of yuan, imposing a significant financial burden. To improve the accessibility of MRD testing, Gene+, in collaboration with JD Health, Volcano Engine, Lighthouse Oncologists, Dongdong Oncology, and Patient Home, has jointly launched the “More Affordable, Healthier Lives: Five-Year Care, Public-Benefit Co-Creation” initiative. This program aims to provide postoperative early-stage cancer patients with a personalized, more precise, and affordable five-year recovery plan centered on MRD testing (baseline plus serial monitoring), helping them achieve a healthy and fulfilling life!

November 14 (Tuesday) at 19:30, VCBeat Select New Product Appreciation Session No. 35,Invited toGene+Director of Health Management, Ren Xin、Director of Oncology Testing Products, Oncology Division, Gene+Liu Meng, presenting an introduction to Gene+ products.

Scan the QR code on the poster to add our assistant and reserve a spot for the live stream.

· Detection of residual trace tumor cells after surgery or radical radiotherapy;

· Monitor treatment response during therapy;

· Post-treatment surveillance for recurrence and metastasis.

·Patients with Stage I–III Postoperative Disease: Assessment of Recurrence Risk

·Stage II–III Patients: Assisting in Precise Adjuvant Therapy Decision-Making

· Follow-up Testing for Patients: Helping to Determine the Frequency of Reexamination

·Pay-per-use, accessible to all

·Customized on Demand, Efficient Detection

·Five Years of Care, Professional Companionship

·Precise and Reliable, Professional Interpretation

·Expert Guidance, Health with Expertise

Ren Xin

Gene+ | Director of Health Management

Senior Genetic Counselor, Senior Health Manager, Psychological Counselor,With 12 years of industry experience, I have delivered over 100 technical and science-popularization training sessions for renowned institutions in the healthcare sector, including major international health industry groups, high-end health management firms, and premium medical providers. I am dedicated to the operational implementation of experiential precision health management services and the integrated practice of tumor prevention and treatment operations.

Liu Meng

Gene+ | Director of Oncology Testing Products, Oncology Business Unit

With nearly a decade of experience in the NGS industry, I am well-versed in the analysis of tumor multi-omics data and product translation, primarily responsible for tumor molecular residual disease (MRD) products.

Gene+, established in 2015, is an innovative high-tech enterprise born out of the broader context of precision medicine. Adhering to a strategy of independent domestic development, the company leverages its large-scale platforms for testing, manufacturing, and data to provide genetic testing products and services across three core business sectors: medicine, technology, and health. This approach has enabled Gene+ to achieve a development trajectory characterized by technological breakthroughs, academic leadership, product innovation, and market leadership.

“Artery Select New Product Showcase” is a live-streaming program under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is to empower every milestone launch of innovative medical products.

Scan the QR code below to contact the assistant and reserve a spot for the live stream.

(If already added, please proactively contact the assistant.)